Literature DB >> 16772120

Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.

Sabine Preisler-Adams1, Ines Schönbuchner, Britta Fiebig, Brigitte Welling, Bernd Dworniczak, Bernhard H F Weber.   

Abstract

A total of 226 index cases from high-risk hereditary breast and ovarian cancer families of German origin who had tested negative for small nucleotide alterations in BRCA1 and BRCA2 were analyzed for gross genomic rearrangements at the two gene loci by the multiplex ligation-dependent probe amplification technique. Six large genomic alterations were identified in BRCA1, while no gross rearrangements were found in BRCA2. The six BRCA1 mutations included two novel mutations including a deletion of exon 5, and a deletion comprising exons 5-7, as well as three distinct gross alterations previously reported, including a deletion of exons 1A, 1B, and 2, two duplications of exon 13, and a deletion of exon 17. To understand the mechanisms underlying the genomic rearrangements within the BRCA1 gene and to provide a simple PCR-based assay for further diagnostic applications, we have defined the molecular breakpoints of the deletion/insertion mutations. In all cases, our data point to a mechanism by which illegitimate crossing over between stretches of direct repeat sequences as small as 9 base pairs (bp) and up to 188 bp may have occurred. Overall, we provide evidence that gross rearrangements within the BRCA1 gene locus may be as frequent as 3% in primarily mutation-negative tested high-risk familial breast and ovarian cancer of German ancestry, while large alterations involving the BRCA2 locus do not appear to play a significant role in disease etiology. These findings have important implications for genetic counseling and testing of high-risk breast and ovarian cancer families.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772120     DOI: 10.1016/j.cancergencyto.2005.07.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  15 in total

1.  Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Paola Concolino; Roberta Rizza; Karl Hackmann; Angelo Minucci; Giovanni Luca Scaglione; Maria De Bonis; Alessandra Costella; Cecilia Zuppi; Evelin Schrock; Ettore Capoluongo
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

2.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

Authors:  Maurizia Dalla Palma; Susan M Domchek; Jill Stopfer; Julie Erlichman; Jill D Siegfried; Jessica Tigges-Cardwell; Bernard A Mason; Timothy R Rebbeck; Katherine L Nathanson
Journal:  Cancer Res       Date:  2008-08-14       Impact factor: 12.701

3.  Genomic rearrangements in BRCA1 and BRCA2: A literature review.

Authors:  Ingrid Petroni Ewald; Patricia Lisboa Izetti Ribeiro; Edenir Inêz Palmero; Silvia Liliana Cossio; Roberto Giugliani; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2009-09-01       Impact factor: 1.771

4.  A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

Authors:  Zaida Garcia-Casado; Ignacio Romero; Antonio Fernandez-Serra; Luis Rubio; Francisco Llopis; Ana Garcia; Pilar Llombart; Jose A Lopez-Guerrero
Journal:  BMC Med Genet       Date:  2011-10-11       Impact factor: 2.103

5.  Correlations between long inverted repeat (LIR) features, deletion size and distance from breakpoint in human gross gene deletions.

Authors:  Nevim Aygun
Journal:  Sci Rep       Date:  2015-02-06       Impact factor: 4.379

6.  BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Ingrid Petroni Ewald; Silvia Liliana Cossio; Edenir Inez Palmero; Manuela Pinheiro; Ivana Lucia de Oliveira Nascimento; Taisa Manuela Bonfim Machado; Kiyoko Abe Sandes; Betânia Toralles; Bernardo Garicochea; Patricia Izetti; Maria Luiza Saraiva Pereira; Hugo Bock; Fernando Regla Vargas; Miguel Ângelo Martins Moreira; Ana Peixoto; Manuel R Teixeira; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016 Apr-Jun       Impact factor: 1.771

7.  Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.

Authors:  Simone Maistro; Natalia Teixeira; Giselly Encinas; Maria Lucia Hirata Katayama; Vivian Dionisio Tavares Niewiadonski; Larissa Garcia Cabral; Roberto Marques Ribeiro; Nelson Gaburo Junior; Ana Carolina Ribeiro Chaves de Gouvêa; Dirce Maria Carraro; Ester Cerdeira Sabino; Maria Del Pilar Estevez Diz; Roger Chammas; Geertruida Hendrika de Bock; Maria Aparecida Azevedo Koike Folgueira
Journal:  BMC Cancer       Date:  2016-12-03       Impact factor: 4.430

8.  A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.

Authors:  Ibrahim Sahin; Hanife Saat
Journal:  Mol Biol Rep       Date:  2021-06-19       Impact factor: 2.316

9.  High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.

Authors:  Petra Vasickova; Eva Machackova; Miroslava Lukesova; Jiri Damborsky; Ondrej Horky; Hana Pavlu; Jitka Kuklova; Veronika Kosinova; Marie Navratilova; Lenka Foretova
Journal:  BMC Med Genet       Date:  2007-06-11       Impact factor: 2.103

10.  Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.

Authors:  Edenir Inêz Palmero; Bárbara Alemar; Lavínia Schüler-Faccini; Pierre Hainaut; Carlos Alberto Moreira-Filho; Ingrid Petroni Ewald; Patricia Koehler Dos Santos; Patricia Lisbôa Izetti Ribeiro; Cristina Brinkmann de Netto Oliveira; Florence Le Calvez-Kelm; Sean Tavtigian; Silvia Liliana Cossio; Roberto Giugliani; Maira Caleffi; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016-05-24       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.